%0 Journal Article
%T Severe Botulism after Intragastric Botulinum Toxin-A Injection: A Case Series
%A Sadiye Gumusyayla
%A Gonul Vural
%J World Journal of Neuroscience
%P 73-83
%@ 2162-2019
%D 2024
%I Scientific Research Publishing
%R 10.4236/wjns.2024.142007
%X Intragastric botulismus toxin-A (BoNT-A) is one of
the new approaches in the treatment of obesity. We aimed to contribute to the
literature by presenting the clinical features, laboratory findings and
treatment responses of iatrogenic botulism cases due to intragastric BoNT-A
administered in our clinic. All detailed medical information was obtained by
accessing the medical records of the patients who were hospitalized and
followed up and treated between September 2022 and December 2022, and the
diagnosis of A.05.1 Botulism was entered according to ICD-10, and whose
clinical findings were compatible with botulism disease and who underwent
intragastric BoNT-A application beforehand. These records were obtained by
examining this information. 10 patients who developed botulism after intragastric
BoNT-A application between 01/09/2022 and 28/02/2023 were followed up in our
clinic. All of the patients were women. The mean age was 35. The mean hospital
stay was 9 days. Only 1 of our cases required intensive care. Good response to
treatment was accepted as a complete or near-complete improvement in the
clinical findings of the patients and all of them had a good response to
treatment. Intragastric BoNT-A administration is a procedure that requires
careful indication with a profit/loss calculation considering the potential
side effects. In addition, attention should be paid to dilution rates and dose
amounts.
%K Intragastric Botulismus Toxin-A
%K Botulism
%K Single Fiber Electromyography
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=132152